Literature DB >> 30664444

Epidemiological Profile and Antimicrobial Resistance Pattern of Enteric Fever in a Tertiary Care Hospital of North India - a Seven Year Ambispective Study.

Anuradha Makkar1, Shilpi Gupta2, Inam Danish Khan3, Rajiv Mohan Gupta4, K S Rajmohan1, Harleen Chopra1, Manisha Gupta5, Sachin Bansal6, Bindu Poonia1, Muqtadir Malik4, Pragyan Swagatika Panda1.   

Abstract

INTRODUCTION: Enteric-fever is a major public-health problem in developing countries emerging as multidrug-resistant, Nalidixic-acid resistant and extremely drug-resistant Salmonella (Pakistan, 2016), has intensified the use of WHO watch/reserve group antimicrobials such as azithromycin and meropenem.
METHODS: This ambispective-study was conducted on 782 non-repeat blood-culture isolates of S. Typhi, S. Paratyphi A and S. Paratyphi B obtained from 29,184 blood cultures received at a 1000-bedded tertiary-care hospital of North-India from 2011-2017. Identification and antibiograms were obtained by Vitek-2 compact and Kirby-Bauer's disc diffusion with resistance to ampicillin, chloramphenicol and cotrimoxazole being labeled as multidrug-resistant. Decreased ciprofloxacin-susceptibility and ciprofloxacin-resistance were defined as MIC 0.125-0.5 and >1 μg/ml.
RESULTS: S. Typhi and S. Paratyphi A in a ratio of 3.9:1 were seen between July-September predominantly distributed between 6-45 year age group. Resistance to co-trimoxazole, chloramphenicol, ceftriaxone and azithromycin was 6.1%, 13.8%, 16.1 and 5.78% respectively. Multidrug-resistant S. typhi and S. paratyphi A were 2.73% and 1.91% respectively.
CONCLUSION: Enteric-fever is a major public-health problem in India. Emergence of multidrug-resistant, Nalidixic-acid resistant and extremely-drug resistant Salmonella mandates ongoing surveillance for targeted empirical therapy and containment of spread. Repeated epidemics call for water, sanitation, hygiene and vaccination strategies to sustain herd-immunity.

Entities:  

Keywords:  antimicrobial resistance; enteric fever; multidrug-resistant Salmonella

Mesh:

Substances:

Year:  2018        PMID: 30664444     DOI: 10.14712/18059694.2018.130

Source DB:  PubMed          Journal:  Acta Medica (Hradec Kralove)        ISSN: 1211-4286


  5 in total

1.  Morbidity, mortality, and emerging drug resistance in Device-associated infections (DAIs) in intensive care patients at a 1000-bedded tertiary care teaching hospital.

Authors:  Inam Danish Khan; Geetanjali Gonimadatala; S Narayanan; Umesh Kapoor; Harleen Kaur; Anuradha Makkar; R M Gupta
Journal:  Med J Armed Forces India       Date:  2021-10-28

2.  Typhoidal Salmonella strains in Pakistan: an impending threat of extensively drug-resistant Salmonella Typhi.

Authors:  Ashfaq Hussain; Luqman Satti; Faisal Hanif; Nadia Midhat Zehra; Saman Nadeem; Tariq Mehmood Bangash; Aqeel Peter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-03       Impact factor: 3.267

3.  Trends, relationships and case attribution of antibiotic resistance between children and environmental sources in rural India.

Authors:  Joseph Mitchell; Manju Purohit; Chris P Jewell; Jonathan M Read; Gaetano Marrone; Vishal Diwan; Cecilia Stålsby Lundborg
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

4.  Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis.

Authors:  Annie J Browne; Bahar H Kashef Hamadani; Emmanuelle A P Kumaran; Puja Rao; Joshua Longbottom; Eli Harriss; Catrin E Moore; Susanna Dunachie; Buddha Basnyat; Stephen Baker; Alan D Lopez; Nicholas P J Day; Simon I Hay; Christiane Dolecek
Journal:  BMC Med       Date:  2020-01-03       Impact factor: 8.775

5.  A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator.

Authors:  Subhash Thuluva; Vikram Paradkar; Ramesh Matur; Kishore Turaga; Subba Reddy Gv
Journal:  Hum Vaccin Immunother       Date:  2022-03-25       Impact factor: 4.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.